262 related articles for article (PubMed ID: 2846954)
1. Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk.
Roots I; Drakoulis N; Ploch M; Heinemeyer G; Loddenkemper R; Minks T; Nitz M; Otte F; Koch M
Klin Wochenschr; 1988; 66 Suppl 11():87-97. PubMed ID: 2846954
[TBL] [Abstract][Full Text] [Related]
2. [Genetic polymorphism in Gilbert-Meulengracht syndrome (GMS)].
Fengler JD; Baumgarten R; Eike E; Eike O; Siegmund W; Franke G; Zschiesche M
Z Gastroenterol; 1993 Feb; 31 Suppl 2():81-2. PubMed ID: 7483725
[TBL] [Abstract][Full Text] [Related]
3. 'Comparison of extremes' approach provides evidence against the modifying role of NAT2 polymorphism in lung cancer susceptibility.
Belogubova EV; Kuligina ESh; Togo AV; Karpova MB; Ulibina JM; Shutkin VA; Hanson KP; Popowski K; Mosyagin I; Cascorbi I; Hirvonen A; Imyanitov EN
Cancer Lett; 2005 Apr; 221(2):177-83. PubMed ID: 15808403
[TBL] [Abstract][Full Text] [Related]
4. Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as a susceptibility factor for lung cancer.
Cascorbi I; Brockmöller J; Mrozikiewicz PM; Bauer S; Loddenkemper R; Roots I
Cancer Res; 1996 Sep; 56(17):3961-6. PubMed ID: 8752164
[TBL] [Abstract][Full Text] [Related]
5. NAT2 fast acetylator genotypes are associated with an increased risk for lung cancer with wildtype epidermal growth factor receptors in Taiwan.
Lee CN; Yu MC; Bai KJ; Chang JH; Fang CL; Hsu HL; Huang BS; Lu PC; Liu HE
Lung Cancer; 2009 Apr; 64(1):9-12. PubMed ID: 18706736
[TBL] [Abstract][Full Text] [Related]
6. [Acetylation polymorphism in lung cancer].
Laredo Quesada JM; Jara Sánchez C; Benítez Rodríguez J; Fernández Gundín MJ; Vargas Castrillón E; Muñoz González JJ; Llerena Ruiz A; Cobaleda Polo J; Pérez-Manga G
An Med Interna; 1991 Feb; 8(2):66-8. PubMed ID: 1893005
[TBL] [Abstract][Full Text] [Related]
7. Genetic predisposition to Balkan endemic nephropathy: ability to hydroxylate debrisoquine as a host risk factor.
Nikolov IG; Chernozemsky IN; Idle JR
IARC Sci Publ; 1991; (115):289-96. PubMed ID: 1820343
[TBL] [Abstract][Full Text] [Related]
8. Mutant genes of cytochrome P-450IID6, glutathione S-transferase class Mu, and arylamine N-acetyltransferase in lung cancer patients.
Roots I; Brockmöller J; Drakoulis N; Loddenkemper R
Clin Investig; 1992; 70(3-4):307-19. PubMed ID: 1355678
[TBL] [Abstract][Full Text] [Related]
9. Sequence variants of NAT1 and NAT2 and other xenometabolic genes and risk of lung and aerodigestive tract cancers in Central Europe.
McKay JD; Hashibe M; Hung RJ; Wakefield J; Gaborieau V; Szeszenia-Dabrowska N; Zaridze D; Lissowska J; Rudnai P; Fabianova E; Mates D; Foretova L; Janout V; Bencko V; Chabrier A; Hall J; Boffetta P; Canzian F; Brennan P
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):141-7. PubMed ID: 18199719
[TBL] [Abstract][Full Text] [Related]
10. A pilot study testing the genetic polymorphism of N-acetyltransferase 2 as a risk factor in lung cancer.
Habalová V; Salagovic J; Kalina I; Stubna J
Neoplasma; 2005; 52(5):364-8. PubMed ID: 16151580
[TBL] [Abstract][Full Text] [Related]
11. Acetylator phenotyping in patients with malignant lymphomas, using caffeine as the metabolic probe.
William BM; Abdel-tawab AM; Hassan EA; Mohamed OF
Pol J Pharmacol; 2004; 56(4):445-9. PubMed ID: 15520499
[TBL] [Abstract][Full Text] [Related]
12. Acetylator phenotype in patients with lung carcinoma--a negative report.
Burgess EJ; Trafford JA
Eur J Respir Dis; 1985 Jul; 67(1):17-9. PubMed ID: 4054252
[TBL] [Abstract][Full Text] [Related]
13. Methyl-CpG binding domain 1 gene polymorphisms and risk of primary lung cancer.
Jang JS; Lee SJ; Choi JE; Cha SI; Lee EB; Park TI; Kim CH; Lee WK; Kam S; Choi JY; Kang YM; Park RW; Kim IS; Cho YL; Jung TH; Han SB; Park JY
Cancer Epidemiol Biomarkers Prev; 2005 Nov; 14(11 Pt 1):2474-80. PubMed ID: 16284366
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome P4501A2: enzyme induction and genetic control in determining 4-aminobiphenyl-hemoglobin adduct levels.
Landi MT; Zocchetti C; Bernucci I; Kadlubar FF; Tannenbaum S; Skipper P; Bartsch H; Malaveille C; Shields P; Caporaso NE; Vineis P
Cancer Epidemiol Biomarkers Prev; 1996 Sep; 5(9):693-8. PubMed ID: 8877060
[TBL] [Abstract][Full Text] [Related]
15. N-acetylation polymorphism in patients with lung cancer and its association with p53 gene mutation.
Oyama T; Kawamoto T; Mizoue T; Yasumoto K; Kodama Y; Mitsudomi T
Anticancer Res; 1997; 17(1B):577-81. PubMed ID: 9066583
[TBL] [Abstract][Full Text] [Related]
16. The distribution of debrisoquine metabolic phenotypes and implications for the suggested association with lung cancer risk.
Caporaso N; Pickle LW; Bale S; Ayesh R; Hetzel M; Idle J
Genet Epidemiol; 1989; 6(4):517-24. PubMed ID: 2777072
[TBL] [Abstract][Full Text] [Related]
17. [Metabolic polymorphisms and the cancer risk: the evaluation of epidemiological studies].
Vineis P; Landi MT; Caporaso N
Med Lav; 1992; 83(6):557-75. PubMed ID: 1296137
[TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphism of N-acetyltransferase 2 in patients with esophageal cancer.
Shibuta J; Eto T; Kataoka A; Inoue H; Ueo H; Suzuki T; Barnard GF; Mori M
Am J Gastroenterol; 2001 Dec; 96(12):3419-24. PubMed ID: 11774959
[TBL] [Abstract][Full Text] [Related]
19. Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction.
Marcus PM; Hayes RB; Vineis P; Garcia-Closas M; Caporaso NE; Autrup H; Branch RA; Brockmöller J; Ishizaki T; Karakaya AE; Ladero JM; Mommsen S; Okkels H; Romkes M; Roots I; Rothman N
Cancer Epidemiol Biomarkers Prev; 2000 May; 9(5):461-7. PubMed ID: 10815690
[TBL] [Abstract][Full Text] [Related]
20. Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose.
Nakachi K; Imai K; Hayashi S; Watanabe J; Kawajiri K
Cancer Res; 1991 Oct; 51(19):5177-80. PubMed ID: 1655248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
